Bank Of Montreal Grifols Sa Transaction History

Bank Of Montreal

$202 Billion
Q4 2024

A detailed history of Bank Of Montreal transactions in Grifols Sa stock. As of the latest transaction made, Bank Of Montreal holds 70,856 shares of GRFS stock, worth $573,933. This represents 0.0% of its overall portfolio holdings.

Number of Shares

70,856

Previous 76,895 7.85%

Holding current value

$573,933

Previous $682,000 22.73%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	SELL	$6.99 - $9.55 $42,212 - $57,672	-6,039 Reduced 7.85%	70,856 $527,000
Q3 2024 Nov 13, 2024	BUY	$6.28 - $9.38 $39,281 - $58,671	6,255 Added 8.85%	76,895 $682,000
Q2 2024 Aug 14, 2024	BUY	$6.27 - $7.7 $48,818 - $59,952	7,786 Added 12.39%	70,640 $445,000
Q1 2024 May 13, 2024	SELL	$5.47 - $11.38 $23,066 - $47,989	-4,217 Reduced 6.29%	62,854 $419,000
Q4 2023 Feb 08, 2024	BUY	$7.71 - $11.56 $28,974 - $43,442	3,758 Added 5.94%	67,071 $775,000
Q3 2023 Nov 01, 2023	BUY	$8.91 - $10.91 $2,993 - $3,665	336 Added 0.53%	63,313 $578,000
Q2 2023 Aug 02, 2023	BUY	$7.14 - $9.29 $449,655 - $585,056	62,977 New	62,977 $576,000
Q2 2022 Aug 11, 2022	SELL	$10.6 - $13.28 $25,736 - $32,243	-2,428 Reduced 2.07%	115,141 $1.44 Million
Q1 2022 May 12, 2022	SELL	$10.37 - $12.73 $566,388 - $695,287	-54,618 Reduced 31.72%	117,569 $1.39 Million
Q4 2021 Feb 11, 2022	BUY	$10.21 - $15.27 $969,776 - $1.45 Million	94,983 Added 123.03%	172,187 $1.96 Million
Q3 2021 Nov 12, 2021	BUY	$14.07 - $17.3 $150,169 - $184,642	10,673 Added 16.04%	77,204 $1.16 Million
Q2 2021 Aug 12, 2021	BUY	$16.62 - $18.94 $1.11 Million - $1.26 Million	66,531 New	66,531 $1.19 Million

Others Institutions Holding GRFS

# of Institutions

169

Shares Held

145M

Call Options Held

166K

Put Options Held

103K

View Full List

About Grifols SA

Ticker GRFS
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 678,910,976
Market Cap $5.5B
Description
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solut...

More about GRFS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of Montreal , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of Montreal with notifications on news.

Account